John M. Goldman

52.5k citations

496 papers · 29.8k indexed · 9 hit papers · h-index 83

Impact in

Hematology top 0.01%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
Genetics top 0.01%
- Chronic Lymphocytic Leukemia Research
- Myeloproliferative Neoplasms: Diagnosis and Treatment

Papers in

Hematology 400
- Chronic Myeloid Leukemia Treatments 289
- Acute Myeloid Leukemia Research 121
- Hematopoietic Stem Cell Transplantation 109
Genetics 253
- Chronic Lymphocytic Leukemia Research 216

Co-authors: Junia V. Melo Michael W. Deininger Jane F. Apperley Richard Szydlo Nicholas C.P. Cross Andreas Hochhaus Jaspal Kaeda Timothy P. Hughes
Journals: Blood (117 papers)British Journal of Haematology (74 papers)The Lancet (16 papers)Leukemia Research (13 papers)Leukemia (11 papers)
Partner nations: United Kingdom United States Germany

In The Last Decade

John M. Goldman

489 papers receiving 28.7k citations

Hit Papers

9 papers align trajectories log scale

Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib 2010 · 674 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2010 Journal of Clinical Oncology
2009 Leukemia
2009 Blood
2009 Journal of Clinical Oncology
2003 New England Journal of Medicine
2003 New England Journal of Medicine
2000 Blood
2000 Blood
1988 Annals of Internal Medicine

Peers

Countries citing papers authored by John M. Goldman

Since Specialization

Citations

This map shows the geographic impact of John M. Goldman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John M. Goldman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John M. Goldman more than expected).

Fields of papers citing papers by John M. Goldman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John M. Goldman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John M. Goldman. The network helps show where John M. Goldman may publish in the future.

Co-authors

The 25 scholars most cited alongside John M. Goldman, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with John M. Goldman Line = papers co-authored together John M. Goldman links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Graft invariant natural killer T-cell dose predicts risk of acute graft-versus-host disease in allogeneic hematopoietic stem cell transplantation Blood ·Aristeidis Chaidos, Scott D. Patterson, Richard Szydlo, Mohammed S. Chaudhry, Francesco Dazzi, Edward Kanfer, Donald M. McDonald, David Marin, Dragana Milojković, Jiří Pavlů, John Davis, Amin Rahemtulla, Katy Rezvani, John M. Goldman, Irene Roberts, Jane F. Apperley, Anastasios Karadimitris	2012	120
2	BCR–ABL Transcript Dynamics Support the Hypothesis That Leukemic Stem Cells Are Reduced during Imatinib Treatment Clinical Cancer Research ·Andrew M. Stein, Dean Bottino, Vijay Modur, Susan Branford, Jaspal Kaeda, John M. Goldman, Timothy P. Hughes, Jerald P. Radich, Andreas Hochhaus	2011	32
3	Adherence Is the Critical Factor for Achieving Molecular Responses in Patients With Chronic Myeloid Leukemia Who Achieve Complete Cytogenetic Responses on Imatinib Journal of Clinical Oncology ·David Marín, Alexandra Bazeos, François-Xavier Mahon, Lina Eliasson, Dragana Milojković, Marco Bua, Jane F. Apperley, Richard Szydlo, Ritti Desai, Kasia Kozlowski, Christos Paliompeis, Victoria Latham, Letizia Foroni, Mathiéu Molimard, Alistair Reid, Katy Rezvani, Hugues de Lavallade, Cristina Guallar, John M. Goldman, Jamshid S. Khorashad Hit paper breakdown →	2010	674
4	Chronic Myeloid Leukemia: A Historical Perspective Seminars in Hematology ·John M. Goldman	2010	80
5	Long Term Adherence to Imatinib Therapy Is the Critical Factor for Achieving Molecular Responses in Chronic Myeloid Leukemia Patients. Blood ·A. Bazeos, Jamshid S. Khorashad, François‐Xavier Mahon, Lina Eliasson, Dragana Milojković, Marco Bua, Jane F. Apperley, Richard Szydlo, Kasia Kozlowski, Christos Paliompeis, Ritti Desai, Letizia Foroni, Alistair Reid, Hugues de Lavallade, Katy Rezvani, John M. Goldman, David Marín	2009	15
6	Man of Aran Robert J. Flaherty, John M. Goldman, Coleman King	2009	2
7	Imatinib for Newly Diagnosed Patients With Chronic Myeloid Leukemia: Incidence of Sustained Responses in an Intention-to-Treat Analysis Journal of Clinical Oncology ·Hugues de Lavallade, Jane F. Apperley, Jamshid S. Khorashad, Dragana Milojković, Alistair Reid, Marco Bua, Richard Szydlo, Eduardo Olavarría, Jaspal Kaeda, John M. Goldman, David Marín	2008	416
8	Finding of Kinase Domain Mutations in Patients With Chronic Phase Chronic Myeloid Leukemia Responding to Imatinib May Identify Those at High Risk of Disease Progression Journal of Clinical Oncology ·Jamshid S. Khorashad, Hugues de Lavallade, Jane F. Apperley, Dragana Milojković, Alistair Reid, Marco Bua, Richard Szydlo, Eduardo Olavarría, Jaspal Kaeda, John M. Goldman, David Marín	2008	144
9	The use of granulocyte–colony‐stimulating factor in volunteer unrelated hemopoietic stem cell donors Transfusion ·Derwood Pamphilon, Elisabeth P. Nacheva, Cristina Navarrete, J. Alejandro Madrigal, John M. Goldman	2008	26
10	Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-α treatment Blood ·Andreas Hochhaus, Brian Druker, Charles L. Sawyers, François Guilhot, Charles A. Schiffer, Jörge E. Cortes, Dietger Niederwieser, Carlo Gambacorti‐Passerini, Richard M. Stone, John M. Goldman, Thomas Fischer, Stephen G. O’Brien, J Reiffers, Manisha Mone, Tillmann Krahnke, Moshe Talpaz, Hagop M. Kantarjian	2007	160
11	Atrial septal endocarditis European Journal of Echocardiography ·Andrew R.J. Mitchell, Paul Leeson, J Timperley, Saul Myerson, Harald Becher, John M. Goldman	2006	2
12	Immune therapy of chronic myelogenous leukemia Leukemia Research ·Robert Peter Gale, Mary M. Horowitz, Moshe Talpaz, David A. Scheinberg, Jeffrey J. Molldrem, Zihai Li, Michele Baccarani, John M. Goldman, S Tura	2005	1
13	Cytogenetic and Molecular Monitoring of Residual Disease in Chronic Myeloid Leukaemia Acta Haematologica ·Jaspal Kaeda, Andrew Chase, John M. Goldman	2002	46
14	A two-colorBCR–ABL probe that greatly reduces the false positive and false negative rates for fluorescence in situ hybridization in chronic myeloid leukemia Genes Chromosomes and Cancer ·Francis Grand, Andrew Chase, Sameena Iqbal, Daniel Nguyen, John L. Lewis, S. B. Marley, Richard J. Davidson, John M. Goldman, M. Y. Gordon	1998	22
15	Characterization of genomic BCR‐ABL breakpoints in chronic myeloid leukaemia by PCR British Journal of Haematology ·J. G. ZHANG, John M. Goldman, Nicholas C.P. Cross	1995	55
16	An atypical myeloproliferative disorder with t(8;13) (p11;q12): a third case British Journal of Haematology ·D. Macdonald, S. M. Sheerin, Nicholas C.P. Cross, Ashley Spencer, John M. Goldman	1994	40
17	The spectrum of molecular alterations in the evolution of chronic myelocytic leukemia. Journal of Clinical Investigation ·HG Ahuja, Menashe Bar‐Eli, Z Arlin, S H Advani, Steven L. Allen, John M. Goldman, D. Snyder, A Foti, M J Cline	1991	146
18	Inhibition of P210BCR/ABL Expression in K562 Cells by Electroporation with an Antisense Oligonucleotide Leukemia & lymphoma ·A. S. Taj, Philippe Martiat, Susheela Dhut, Tracy Chaplin, C. Dowding, K. H. Th'ng, Ido Goldstein, G Q Daley, B D Young, John M. Goldman	1990	15
19	Mechanisms of viral leukaemogenesis Churchill Livingstone eBooks ·John M. Goldman, Oswald Jarrett	1984	28
20	Meningoencephalitis associated with Chlamydia trachomatis infection. BMJ ·John M. Goldman, C S McIntosh, G.P. Calver, R.M. Perinpanayagam	1983	7

About John M. Goldman

John M. Goldman is a scholar working on Hematology, Genetics, Rheumatology, Immunology and Oncology, having authored 496 papers that have together received 29.8k indexed citations. Recurring topics across this work include Chronic Myeloid Leukemia Treatments (289 papers), Chronic Lymphocytic Leukemia Research (216 papers), Eosinophilic Disorders and Syndromes (123 papers), Acute Myeloid Leukemia Research (121 papers), Hematopoietic Stem Cell Transplantation (109 papers), Acute Lymphoblastic Leukemia research (59 papers), Lymphoma Diagnosis and Treatment (33 papers) and T-cell and B-cell Immunology (31 papers). The work is most often cited by research in Hematology (22.2k citations), Genetics (14.3k citations), Rheumatology (8.6k citations), Immunology (4.0k citations) and Oncology (5.1k citations). John M. Goldman has collaborated with scholars based in United Kingdom, United States and Germany. Frequent co-authors include Junia V. Melo, Michael W. Deininger, Jane F. Apperley, Richard Szydlo, Nicholas C.P. Cross, Andreas Hochhaus, Jaspal Kaeda, Timothy P. Hughes, Eduardo Olavarría and Jerald P. Radich. Their work appears in journals such as Blood, British Journal of Haematology, The Lancet, Leukemia Research and Leukemia.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact